Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.66 |
| ▸ | HTR6 | P50406 | 2/20 | 0.66 |
| ▸ | DRD2 | P14416 | 1/20 | 0.66 |
| ▸ | HTR1A | P08908 | 13/20 | 0.65 |
| ▸ | HTR7 | P34969 | 8/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.65 |
| ▸ | MPO | P05164 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6580604 | 0.97 | DRD2 (0.70) | KCNH2HTR6DRD2HTR1AHTR7 | |
| SCHEMBL6586104 | 0.94 | KCNH2 (0.66) | KCNH2HTR6DRD2HTR1AHTR7 | |
| SCHEMBL6582633 | 0.88 | DRD2 (0.68) | DRD2HTR1A | |
| SCHEMBL6583162 | 0.86 | DRD2 (0.70) | KCNH2HTR6DRD2HTR1AHTR7 | |
| SCHEMBL28500421 | 0.85 | HTR1A (0.71) | KCNH2DRD2HTR1AHTR7SLC6A4 | |
| SCHEMBL6582782 | 0.85 | KCNH2 (0.66) | KCNH2HTR6DRD2HTR1AHTR7 | |
| Hydrochloric Acid SCHEMBL28505002 | 0.85 | HTR1A (0.70) | KCNH2DRD2HTR1AHTR7SLC6A4 | |
| SCHEMBL6582590 | 0.84 | DRD2 (0.67) | DRD2HTR1A | |
| SCHEMBL6582422 | 0.84 | KCNH2 (0.62) | KCNH2HTR6DRD2HTR1AHTR7 | |
| SCHEMBL9368593 | 0.83 | HTR1A (0.92) | KCNH2HTR6HTR1AHTR7SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1246815-B1 | PHENYLPIPERAZINYL DERIVATIVES | LUNDBECK & CO AS H (DK) | 2004-03-17 | — | — | EP | disclosed |
| CN-1437596-A | Phenylpiperazinyl derivatives | LUNDBECK & CO AS H (DK) | 2003-08-20 | — | — | CN | disclosed |
| US-20030083336-A1 | Phenylpiperazinyl derivatives | H. LUNDBECK A/S (DK) | 2003-05-01 | — | — | US | disclosed |
| EP-1246815-A1 | PHENYLPIPERAZINYL DERIVATIVES | H. Lundbeck A/S (DK) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001049677-A1 | PHENYLPIPERAZINYL DERIVATIVES | H. LUNDBECK A/S (DK) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083336-A1 | Phenylpiperazinyl derivatives | DRD4, DRD2, DRD3 | KCNH2 341/4885HTR6 72/4885DRD2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.